Posted in M&A / Deals Biogen swoops on Apellis with $5.6bn offer March 31, 2026 Pharmaphorum In today’s second sizeable M A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology. M&A / DealsNephrologyRead full story